The current meta-analysis shows that the benefits of SGLT2 inhibitors on kidney disease progression extend to patients irrespective of diabetes status and in patients with chronic kidney disease irrespective of their primary kidney diagnosis. This evidence concerns the gene SLC5A2 and chronic kidney disease.